BriaCell announces data on Bria-IMT to be presented at ASCO 2024

BriaCell Therapeutics announces positive clinical data of its lead product candidate, Bria-IMT, to be presented in one oral presentation session, two poster sessions, and one abstract on the updated clinical data of BriaCell’s randomized Phase 2 study evaluating Bria-IMT in patients with advanced metastatic breast cancers at the 2024 American Society of Clinical Oncology, ASCO, Annual Meeting taking place taking place May 31 – June 4, 2024 at McCormick Place, Chicago, IL. Phase 2 clinical data of the Bria-IMT regimen in 54 advanced metastatic breast cancer patients who failed multiple prior treatments including ADCs and immune check point inhibitors are presented. Clinical Efficacy: Median progression free survival of 4.1 months in heavily pretreated ADC resistant patients; PFS of 3.9 months in patients treated with planned pivotal Phase 3 formulation is double the PFS of patients in similar studies who received physician’s treatment of choice; Overall response rate of 9.5% and clinical benefit rate of 55% in evaluable patients compares favorably with the literature; 5/6 of evaluable patients with intracranial lesions treated with Bria-IMT in all BriaCell studies had intracranial responses, including complete and partial responses